DBV Technologies (NASDAQ:DBVT) Coverage Initiated at StockNews.com

Analysts at StockNews.com began coverage on shares of DBV Technologies (NASDAQ:DBVT) in a research note issued to investors on Tuesday. The firm set a “hold” rating on the stock.

Separately, HC Wainwright reduced their price target on shares of DBV Technologies from $20.00 to $10.00 and set a “buy” rating for the company in a research report on Wednesday, May 8th.

DBV Technologies Stock Up 2.3 %

Shares of NASDAQ DBVT opened at $0.80 on Tuesday. The company has a market cap of $77.10 million, a P/E ratio of -0.95 and a beta of 0.69. DBV Technologies has a 52 week low of $0.50 and a 52 week high of $3.70. The business has a 50-day simple moving average of $1.02 and a two-hundred day simple moving average of $1.43.

DBV Technologies (NASDAQ:DBVT) last announced its quarterly earnings results on Tuesday, May 7th. The company reported ($0.28) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.44) by $0.16. The firm had revenue of $1.41 million for the quarter, compared to the consensus estimate of $3.20 million. DBV Technologies had a negative net margin of 530.89% and a negative return on equity of 56.76%. Equities research analysts anticipate that DBV Technologies will post -1.22 EPS for the current year.

Institutional Trading of DBV Technologies

An institutional investor recently bought a new position in DBV Technologies stock. Cowen AND Company LLC purchased a new stake in shares of DBV Technologies S.A. (NASDAQ:DBVT) during the fourth quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm purchased 50,986 shares of the company’s stock, valued at approximately $49,000. Hedge funds and other institutional investors own 71.74% of the company’s stock.

About DBV Technologies

DBV Technologies SA, a clinical-stage biopharmaceutical company, engages in the research and development of epicutaneous immunotherapy products. Its product pipeline comprising Viaskin Peanut, an immunotherapy product, which has completed Phase 3 clinical trial for the treatment of peanut allergies; and Viaskin Milk which is in Phase 1/2 clinical trial for the treatment of immunoglobulin E (IgE) mediated or cow's milk protein allergy and eosinophilic esophagitis.